前驱期突触核蛋白病评定量表:REM睡眠行为障碍患者中的评估
本研究在北美前驱期突触核蛋白病(NAPS)队列中评估前驱期突触核蛋白病评定量表(PSRS)的心理测量学特性与信度。348例无显性帕金森病、路易体痴呆或多系统萎缩的REM睡眠行为障碍患者接受PSRS评定,各领域与独立测量工具呈中度至强相关,评定者间和评定者内信度良好至优秀,提示PSRS具有初步有效性。
要点
- PSRS各领域与多个独立临床负担测量工具呈中度至强相关。
- PSRS评定者间和评定者内信度均值范围为0.76至0.98,信度良好至优秀。
- PSRS在RBD患者中测量突触核蛋白病临床负担具有初步有效性。
核心结论
- 在大型多中心RBD队列中,PSRS各领域与多个独立临床负担测量工具呈中度至强相关,信度良好至优秀,证明PSRS具有初步有效性。
研究设计与样本
- 研究分析2022年8月至2025年6月期间北美前驱期突触核蛋白病(NAPS)队列中无显性帕金森病、路易体痴呆或多系统萎缩的参与者(n=348)的PSRS评分。
- PSRS由临床评定者依据临床判断评估各领域症状体征,每领域0分至最高2-4分,总分最高25分,领域包括认知、行为/精神、运动-轴向、运动-附肢、自主神经、睡眠和感觉。
- 采用贝叶斯广义线性混合效应模型量化20个不同评定者对20个病例示例方案的重测信度。
主要发现
- 认知领域与蒙特利尔认知评估(r=-0.42)和临床痴呆评定量表-总框分(r=0.77)显著相关(p<0.0001)。
- 行为/精神领域与神经精神问卷(r=0.38)显著相关(p<0.0001)。
- 运动-轴向和运动-附肢领域与MDS-UPDRS运动部分分别相关(r=0.65和0.75,p<0.0001)。
- 自主神经领域与帕金森病自主神经功能障碍结局量表(r=0.39)、睡眠领域与Epworth嗜睡量表(r=0.23)、感觉领域与简短气味识别测验(r=-0.66)均显著相关(p<0.0001)。
- PSRS总分与功能评估量表(r=0.47)、Schwab和England日常生活活动能力(r=-0.58)及临床总体严重程度印象(r=0.29)显著相关(p<0.0001)。
关键数值与推荐
- PSRS每领域评分范围0分(无)至最高2-4分,总分最高25分。
- 评定者间和评定者内信度均值范围为0.76至0.98。
- 各领域与独立测量工具的相关性均在p<0.0001水平显著。
临床怎么用
- PSRS可用于评估REM睡眠行为障碍患者的前驱期突触核蛋白病临床负担,涵盖认知、行为/精神、运动、自主神经、睡眠和感觉多个领域。
- PSRS评分与多种独立临床测量工具相关,可作为临床试验中量化前驱期疾病负担的初步工具。
局限性
- 研究仅提供初步有效性证据,需进一步验证。
- 重测信度分析仅基于20个病例示例方案和20名评定者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Clinical trials in REM sleep behavior disorder (RBD) to delay or prevent the development of Parkinson disease (PD), dementia with Lewy bodies (DLBs), and multiple system atrophy (MSA) will soon begin. The Prodromal Synucleinopathy Rating Scale (PSRS) was developed to capture the breadth and severity of clinical burden of prodromal disease. We analyzed the clinicometric properties and reliability of the PSRS in the North American Prodromal Synucleinopathy (NAPS) cohort. METHODS: PSRS ratings were examined for visits conducted from August 2022-June 2025 on participants who did not have overt PD, DLB, or MSA (n = 348). Clinician raters used clinical judgement to evaluate signs and symptoms within each domain. Scores range from 0 (none) to a maximum of 2-4 points per domain, with a total maximum score of 25. The domains include cognitive (COG), behavioral/psychiatric (PSY), motor-axial (MAX), motor-appendicular (MAP), autonomic (AUT), sleep (SLP), and sensory (SEN). Spearman correlations were generated between ratings for each domain, the total sum score (SUM), and with independent measures of similar constructs. Test-retest reliability for 20 case examples protocols among 20 different raters was quantified using Bayesian generalized linear mixed-effects model. RESULTS: Participants were 79% male with a mean age of 65.4 ± 10.4 years. The following correlations were statistically significant at p < 0.0001: COG with Montreal Cognitive Assessment (r = -0.42) and Clinical Dementia Rating-Sum of Boxes (r = 0.77); PSY with Neuropsychiatric Inventory-Questionnaire (r = 0.38); MAX and MAP with the Movement Disorders Society-Unified Parkinson Disease Rating Scale Motor (r = 0.65 and 0.75, respectively); AUT with Scales for Outcomes in Parkinson's Disease-Autonomic Dysfunction (r = 0.39); SLP with Epworth Sleepiness Scale (r = 0.23); and SEN with Brief Smell Identification Test (r = -0.66). The PSRS SUM was correlated with the Functional Assessment Scale (r = 0.47), Schwab and England Activities of Daily Living (r = -0.58), and Clinician Global Impression of Severity (r = 0.29, p < 0.0001 for each). The inter-rater and intrarater reliability means ranged from 0.76 to 0.98. DISCUSSION: In this large multicenter RBD cohort, moderate to strong correlations were observed between PSRS domains and multiple independent measures of clinical burden. Reliability data were good to excellent. These findings demonstrate preliminary validity for the PSRS for measuring synucleinopathy clinical burden in those with RBD. TRIAL REGISTRATION INFORMATION: NCT05826457 NAPS Consortium Website: naps-rbd.org/.
引用
- Boeve BF, Nie Y, Lu R, et al. The Prodromal Synucleinopathy Rating Scale: An Assessment in Patients With REM Sleep Behavior Disorder. Neurology. 2026. PMID: 42302227. doi:10.1212/WNL.0000000000218176
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。